Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer

In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.

Trial Details

NCT ID
NCT03961373
Phase
PHASE3
Sponsor
University of Siena
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Gastrectomy with D2 lymphadenectomy
  • Gastrectomy with D2plus lymphadenectomy
Locations (sample)
  • Siena, Italy|43.31822,11.33064

Key Eligibility Criteria

  • Age equal or greater than 18 years
  • IIA-IIIC histologically proven primary gastric adenocarcinoma, before the treatment with NAC. Not including gastro-oesophageal junction/cardia carc…
  • Lack in CT scan of following:
  • Mediastinal lymph nodes

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →